Skip to main content
. 2021 Sep 27;12:743979. doi: 10.3389/fphar.2021.743979

TABLE 3.

Costs and outcome results in the base case analysis.

Country Results Methylated status Unmethylated status
RT alone RT plus TMZ RT alone RT plus TMZ
China Costs (¥) 33,900.05 153,290.52 29,170.33 124,889.19
Life-years 0.8 1.28 0.77 0.93
QALYs 0.53 0.88 0.57 0.61
ICER 342,162.55 2,453,399.26
US Costs ($) 54,796.09 85,975.87 47,685.92 77,357.47
Life-years 0.8 1.28 0.77 0.93
QALYs 0.53 0.88 0.57 0.61
ICER 89,358.51 a 760,520.78

QALY: quality-adjusted life-years; ICER: incremental cost-effectiveness ratio; RT: radiotherapy; TMZ: temozolomide.

a

Below the willingness-to-pay threshold of $10000 per QALY gained.